Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.53 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23001085 | 0.96 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL9027639 | 0.96 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL515226 | 0.96 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL52780 | 0.96 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL20472539 | 0.96 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL5190825 | 0.89 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL5475892 | 0.89 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL1643923 | 0.89 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL23166803 | 0.85 | ALDH1A1 (0.53) | FABP3ALDH1A1LPAR1ENPP2LPAR4 | |
| SCHEMBL23091273 | 0.85 | ALDH1A1 (0.53) | FABP3ALDH1A1LPAR1ENPP2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241578-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2019-08-08 | — | — | US | disclosed |
| US-10287290-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | DREXEL UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20170190709-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | UNIV DREXEL (US) | 2017-07-06 | — | — | US | disclosed |
| US-9616065-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | DREXEL UNIVERSITY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20160074408-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2016-03-17 | — | — | US | disclosed |
| WO-2014172453-A2 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | PHILADELPHIA HEALTH AND EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE (US) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241578-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | SLC18A2, SLC6A2, SLC1A2 | FABP3 351/4885P2RY10 2097/4885GPR34 1607/4885 |
| US-20170190709-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | SLC18A2, SLC6A2, SLC1A2 | FABP3 351/4885P2RY10 2097/4885GPR34 1607/4885 |
| US-10287290-B2 | Compositions useful in treating brain-related diseases or disorders and methods using same | SLC18A2, SLC6A2, SLC1A2 | FABP3 533/4885P2RY10 1814/4885GPR34 1839/4885 |
| US-20160074408-A1 | NOVEL COMPOSITIONS USEFUL IN TREATING BRAIN-RELATED DISEASES OR DISORDERS AND METHODS USING SAME | SLC18A2, SLC18A3, SLC1A2 | FABP3 404/4885P2RY10 2189/4885GPR34 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.